Gan & Lee Pharmaceuticals.

This phase 3 study tests an investigational injection called GZR18 to help adults with obesity or overweight lose weight. About 630 participants in China will receive either the drug or a placebo, and researchers will measure how much weight they lose over time. The goal is to se…

This study tests a new insulin (GZR4) that is injected just once a week, compared to a standard daily insulin (degludec), in 620 adults with type 2 diabetes who already use basal insulin. The goal is to see if the weekly shot controls blood sugar just as well or better, with fewe…

This study tests two experimental injections, GZR102 (once a week) and GZR18 (every two weeks), in adults with type 2 diabetes whose blood sugar is not well controlled on current GLP-1 medications. About 90 Chinese participants will receive one of the two treatments to see which …

This study tests a new injectable medicine called GZR18 in about 1,100 Chinese adults with type 2 diabetes whose blood sugar is not well controlled by current pills. The goal is to see if GZR18 can lower blood sugar and help with weight loss compared to standard treatments. Parti…

This study tests a new insulin called GZR4 that is given once a week, compared to the standard daily insulin, in 580 adults with type 2 diabetes who already use insulin. The goal is to see if the weekly shot controls blood sugar just as well or better, with fewer injections. Part…

This study tests an investigational injection called GZR18 in 274 Chinese adults with type 2 diabetes whose blood sugar is not well controlled by diet and exercise alone. The main goal is to see if GZR18 can safely lower HbA1c (a measure of average blood sugar) compared to a plac…

This study tests a new once-weekly insulin (GZR4) against a standard daily insulin in adults with type 2 diabetes who have never used insulin before. About 580 participants will receive either the weekly shot plus other diabetes pills or the daily shot plus other pills. The goal …

This study looks at how a single dose of the experimental drug GZR4 injection behaves in people with mild, moderate, or severe liver impairment compared to those with normal liver function. The goal is to understand the drug's safety and how the body processes it. 36 adults with …